PEP005 topical ingenol mebutate gel: Additional Phase III data

Additional data from the double-blind, U.S. Phase III REGION-Ib trial in 203 patients showed that a 0.05% concentration of topical PEP005 applied daily for 2 consecutive days led to a complete clearan...